Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBV NYSE:JNJ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$213.77+2.1%$209.49$180.25▼$244.81$369.98B0.326.62 million shs7.22 million shsJNJJohnson & Johnson$229.97+0.5%$234.70$149.04▼$251.71$551.06B0.277.86 million shs9.67 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie+2.00%+2.86%+2.63%-6.56%+15.15%JNJJohnson & Johnson+0.51%+2.46%-1.84%-6.09%+50.86%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$213.77+2.1%$209.49$180.25▼$244.81$369.98B0.326.62 million shs7.22 million shsJNJJohnson & Johnson$229.97+0.5%$234.70$149.04▼$251.71$551.06B0.277.86 million shs9.67 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie+2.00%+2.86%+2.63%-6.56%+15.15%JNJJohnson & Johnson+0.51%+2.46%-1.84%-6.09%+50.86%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.88Moderate Buy$253.4318.55% UpsideJNJJohnson & Johnson 2.74Moderate Buy$253.0410.03% UpsideCurrent Analyst Ratings BreakdownLatest JNJ and ABBV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026ABBVAbbVie EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$235.005/14/2026ABBVAbbVie Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$294.00 ➝ $298.005/13/2026JNJJohnson & Johnson Johnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Outperform5/13/2026JNJJohnson & Johnson Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$265.005/1/2026ABBVAbbVie GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$249.004/30/2026ABBVAbbVie DZ BankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/30/2026ABBVAbbVie Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$262.00 ➝ $265.004/30/2026ABBVAbbVie Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$270.00 ➝ $278.004/30/2026ABBVAbbVie Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$240.004/30/2026ABBVAbbVie Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$234.004/24/2026JNJJohnson & Johnson Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B+) ➝ Buy (B)(Data available from 5/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$61.16B6.18$15.47 per share13.82($3.74) per share-57.16JNJJohnson & Johnson$94.19B5.88$14.19 per share16.21$33.73 per share6.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.23B$2.03105.3113.110.725.79%-576.45%13.39%7/30/2026 (Estimated)JNJJohnson & Johnson$26.80B$8.6526.5918.282.2421.83%32.60%13.29%7/15/2026 (Estimated)Latest JNJ and ABBV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/29/2026Q1 2026ABBVAbbVie$2.59$2.65+$0.06$0.39$14.72 billion$15.00 billion4/14/2026Q1 2026JNJJohnson & Johnson$2.68$2.70+$0.02$2.14$23.60 billion$24.06 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.923.24%+6.80%340.89%53 YearsJNJJohnson & Johnson$5.202.26%+5.25%60.12%64 YearsLatest JNJ and ABBV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/14/2026JNJJohnson & Johnsonquarterly$1.342.23%5/26/20265/26/20266/9/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVieN/A0.800.68JNJJohnson & Johnson0.461.030.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%JNJJohnson & Johnson69.55%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.06%JNJJohnson & Johnson0.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie57,0001.77 billion1.77 billionOptionableJNJJohnson & Johnson138,2002.41 billion2.40 billionOptionableJNJ and ABBV HeadlinesRecent News About These CompaniesHow Investors May Respond To Johnson & Johnson (JNJ) Advancing Immunology, Cardiology And Surgical Robotics Platforms1 hour ago | finance.yahoo.comJohnson & Johnson (JNJ) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptMay 19 at 3:02 PM | seekingalpha.comThese 3 Dividend Stocks Are as Close to a Sure Thing as Investing GetsMay 19 at 2:51 PM | fool.comJ&J's Pipeline Progress & New Drugs Promise Stronger Long-Term GrowthMay 19 at 12:21 PM | zacks.comThis Will Be Johnson and Johnson's Stock Price in 2027May 19 at 10:21 AM | 247wallst.comJohnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on ItMay 19 at 10:01 AM | zacks.comPortal Innovations and New Brunswick Development Corporation Collaborate with Johnson & Johnson to Name the Johnson & Johnson Exchange at the New Jersey Innovation Hub in HELIX, Advancing the State's Life Sciences LeadershipMay 19 at 9:00 AM | businesswire.comJohnson And Johnson Catheter Launch Adds New Angle To JNJ ValuationMay 19 at 8:03 AM | finance.yahoo.comMeet the Dividend King With a Higher Credit Rating Than the U.S. GovernmentMay 19 at 8:03 AM | fool.comResona Asset Management Co. Ltd. Cuts Position in Johnson & Johnson $JNJMay 19 at 6:35 AM | marketbeat.comProfund Advisors LLC Acquires 9,285 Shares of Johnson & Johnson $JNJMay 19 at 6:18 AM | marketbeat.comJohnson & Johnson $JNJ Shares Sold by ProShare Advisors LLCMay 19 at 6:18 AM | marketbeat.comHandelsbanken Fonder AB Increases Position in Johnson & Johnson $JNJMay 19 at 4:22 AM | marketbeat.comJohnson & Johnson $JNJ Shares Sold by HighTower Advisors LLCMay 19 at 4:05 AM | marketbeat.comEnvestnet Portfolio Solutions Inc. Increases Position in Johnson & Johnson $JNJMay 19 at 4:04 AM | marketbeat.comJohnson & Johnson $JNJ Shares Sold by Gabelli Funds LLCMay 19 at 3:47 AM | marketbeat.comIs Johnson & Johnson (JNJ) One of the Best “Dogs of the Dow” Stocks to Buy for the Rest of 2026?May 18 at 7:53 PM | finance.yahoo.comIs Johnson & Johnson (JNJ) One of the Best “Dogs of the Dow” Stocks to Buy for the Rest of 2026?May 18 at 6:30 PM | insidermonkey.comCancer Stocks That Are Advancing the Future of Oncology CareMay 18 at 1:01 PM | zacks.comWhy Johnson & Johnson (JNJ) is a Great Dividend Stock Right NowMay 18 at 12:47 PM | zacks.comSupreme Court Rejects Drugmakers’ Challenge to Medicare Price Negotiation ProgramMay 18 at 10:30 AM | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 2026AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?By Thomas Hughes | April 29, 2026The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the BeatBy Jessica Mitacek | May 2, 2026JNJ and ABBV Company DescriptionsAbbVie NYSE:ABBV$213.77 +4.36 (+2.08%) Closing price 05/19/2026 03:59 PM EasternExtended Trading$214.06 +0.28 (+0.13%) As of 05/19/2026 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Johnson & Johnson NYSE:JNJ$229.97 +1.05 (+0.46%) Closing price 05/19/2026 03:59 PM EasternExtended Trading$228.82 -1.15 (-0.50%) As of 05/19/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas HIVE Weaponizes Power for an AI Pivot Why Home Depot’s Sell-Off Could Become a Huge Opportunity Brady Corp Wires Up a Massive AI-Powered Breakout AAPL: Forget the iPhone—Services Will Drive the Next Phase of Growth Nebius Group Pulls Back 9% After a Downgrade Despite Strong Earnings A Deep Dive Into NVIDIA’s Latest Portfolio Moves The $132 Billion Infrastructure Pivot You Might Have Missed The Pentagon's AI Pivot Supercharges Defense Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
